As the field of psychedelic medicine moves from the fringes of counterculture into the mainstream of psychiatric research, the need for standardized protocols has never been more urgent. While substances like MDMA and psilocybin have shown remarkable promise in treating some of the most stubborn mental health disorders, the path toward regulatory approval has been hampered by a lack of consistency in how trials are conducted and reported. In a landmark effort to bring much-needed rigour to the field, an international team of researchers has unveiled a new set of guidelines designed to standardize the way the "context" of a psychedelic experience is documented.
The study, led by experts from McGill University, Imperial College London, and the University of Exeter, represents a significant turning point for the industry. Published in the prestigious journal Nature Medicine, the researchers have introduced the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines. This 30-item checklist marks the first global consensus on how to account for the psychosocial factors that can radically alter the outcome of psychedelic-assisted therapy. By focusing on the environment and the patient’s mindset—often referred to as "set and setting"—the researchers aim to solve a problem that has plagued the field for decades: the unpredictability of results across different clinical environments.
For years, the psychedelic research community has operated under a widely acknowledged but rarely addressed flaw. Unlike traditional pharmaceuticals, where a pill is expected to produce a relatively uniform physiological effect regardless of where it is administered, psychedelics are uniquely sensitive to external and internal variables. The ReSPCT guidelines acknowledge that a drug’s chemical interaction with the brain is only one part of the therapeutic equation. The surrounding environment, the relationship with the therapist, and the patient’s own expectations are equally influential in determining whether a session leads to a breakthrough or a setback.
The Challenge of Context in Modern Medicine
The introduction of these guidelines challenges the foundational way that psychoactive drugs are typically studied in Western medicine. Traditionally, the gold standard for clinical trials involves isolating a single variable—the drug—while controlling or eliminating all other outside influences. Scientists strive for a sterile, neutral environment to ensure that any observed change in the patient is purely the result of the pharmacological agent. However, the researchers behind the ReSPCT guidelines argue that in the case of psychedelics, this approach is fundamentally misguided.
"For decades, we’ve known that psychedelics don’t work in isolation. The person’s mindset, the therapy room, even the music playing all influence outcomes," said co-lead author Chloé Pronovost-Morgan, a researcher at McGill University and Imperial College London. "Two trials using the same psychedelic drug, at the same dose, can produce completely different results depending on the environment."
This variability has historically led to inconsistent study results, which in turn creates significant hurdles for regulatory bodies like the U.S. Food and Drug Administration (FDA) and Health Canada. When two different labs report vastly different outcomes for the same substance, it becomes difficult for regulators to determine the drug’s true efficacy and safety profile. By recognizing that context is not a "noise" to be filtered out but a crucial component to be studied directly, the ReSPCT guidelines offer a new framework for understanding how these treatments actually function in a real-world setting.
To develop these standards, the research team employed a Delphi consensus study, a structured communication technique used to reach a high-level agreement among a panel of experts. The study brought together 89 leading experts from 17 different countries, facilitating a multi-round debate to distill the most important factors in a psychedelic experience. The resulting 30-item checklist covers a wide range of psychosocial factors, ensuring that researchers everywhere are looking at the same variables when they report their findings.
Why guidelines matter
The practical implications of these guidelines extend far beyond the walls of academic laboratories. The absence of such standards has already had tangible consequences for the future of mental health care. A prominent example cited by the researchers is the recent decision by the U.S. Food and Drug Administration to reject a proposal for MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Despite years of advocacy and positive anecdotal reports, the FDA pointed to inconsistent reporting across various trials as a primary reason for the rejection. Without a standardized way to report on the therapeutic environment and the mindset of the participants, the agency found it difficult to validate the data presented.
Pronovost-Morgan explained that this lack of standards creates a bottleneck in the drug development pipeline. If the scientific community cannot agree on how to measure the "setting" of a trial, it cannot provide the level of evidence required for federal approval. The ReSPCT guidelines are intended to bridge this gap, offering a standard framework that makes trial outcomes more consistent, comparable, and ultimately, more reliable for regulators.
Leor Roseman, a co-senior author from the University of Exeter, emphasized that these guidelines are essential for distinguishing psychedelics from other classes of psychiatric medications. "Having clear guidelines for contextual considerations is essential to understand the effects of psychedelics and how they work differently from other psychiatric medications," Roseman said. "Our guidelines will also help in replicating results and understanding the true therapeutic potential of psychedelics."
Unlike standard antidepressants, which are often taken daily to manage symptoms over a long period, psychedelic-assisted therapy typically involves a limited number of high-dose sessions integrated with intensive psychotherapy. In this model, the "drug" acts more like a catalyst for a psychological process rather than a standalone cure. Therefore, the conditions under which that catalyst is introduced—the comfort of the room, the trust between the patient and the clinician, and even the selection of music—become integral to the treatment itself.
The urgency of this work is underscored by the current global mental health crisis. With rates of PTSD, depression, and anxiety reaching record highs, many patients find that existing treatments are insufficient. Traditional Selective Serotonin Reuptake Inhibitors (SSRIs) and talk therapy do not work for everyone, leaving millions of people searching for alternatives.
"There is immense public interest in psychedelic therapies, particularly for individuals suffering from debilitating mental health conditions like PTSD, depression and anxiety, which have not responded to existing treatments," said co-senior author Kyle Greenway, Assistant Professor in McGill’s Division of Social and Transcultural Psychiatry and a researcher at the Lady Davis Institute for Medical Research. "Our guidelines offer a new gold standard for psychedelic research, helping bring these treatments to those who need them most."
The ReSPCT guidelines represent more than just a checklist; they are a call for a more holistic approach to psychiatric science. By documenting variables such as the physical layout of the treatment room, the specific training of the therapists involved, and the preparation given to the patient before the session, researchers can begin to map out exactly which environments produce the best therapeutic results. This data-driven approach to "set and setting" could eventually allow clinicians to tailor the environment to the specific needs of an individual patient, further increasing the success rate of the therapy.
The global nature of the Delphi study ensures that these guidelines are not limited to one specific cultural or institutional perspective. With contributors from 17 countries, the ReSPCT framework accounts for the diverse ways in which psychedelic therapy is being explored around the world. This international consensus is vital for the creation of a global market for these treatments, allowing data from a trial in London to be accurately compared with a trial in Montreal or Melbourne.
Looking ahead, the research team is already taking steps to ensure that these guidelines are integrated into the broader scientific community. In October, a three-day workshop will be held to discuss the implementation of the ReSPCT standards. Funded by McGill University’s Healthy Brains, Healthy Lives initiative, the event will gather leading experts in psychedelics and neuroscience. The goal of the workshop is to move the guidelines from the pages of Nature Medicine into active research protocols and, eventually, into clinical practice.
The workshop will focus on the practicalities of the 30-item checklist, discussing how researchers can efficiently collect and report this data without overtaxing the trial process. By fostering a dialogue between neuroscientists, clinicians, and regulatory experts, the organizers hope to create a roadmap for the future of the field—one where the "magic" of the psychedelic experience is supported by the rigour of standardized science.
As the medical community continues to navigate the complexities of these powerful substances, the ReSPCT guidelines provide a necessary foundation. By acknowledging the profound impact of the human element in medicine, this international collaboration has set the stage for a new era of mental health treatment—one that is as much about the environment of healing as it is about the chemistry of the brain. Through these efforts, the hope is that the next generation of psychiatric treatments will be not only more effective but also more accessible to those who have long been waiting for a breakthrough.
